Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Cumulative Impact of High Inflation - Forecast 2023-2030- Product Image

Sale

Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Cumulative Impact of High Inflation - Forecast 2023-2030

Report
233 Pages
May 2023
Region: Global
360iResearch™
ID: 5337548

UP TO €865EUR$895USD£750GBP OFF until Jun 30^th 2023

The Global Cancer Immunotherapy Market size was estimated at USD 69.63 billion in 2022 and expected to reach USD 73.38 billion in 2023, at a CAGR 5.53% to reach USD 107.11 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Immunotherapy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Immunotherapy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. The Cell Therapies is further studied across Chimeric Antigen Receptor T Cell Therapy and Dendritic Cells. The Checkpoint Inhibitors is further studied across Cytotoxic T-Lymphocyte-Associated Protein-4 and Programmed Death 1 & Programmed Death Ligand 1. The Immunomodulators is further studied across Granulocyte-Macrophage Colony-Stimulating Factor, Interferons, Interleukins, and Oncolytic Virus. The Monoclonal Antibodies is further studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Naked Monoclonal Antibodies. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines. The Monoclonal Antibodies is projected to witness significant market share during forecast period.
Based on Function, market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer. The Melanoma is projected to witness significant market share during forecast period.
Based on End-User, market is studied across Cancer Research Institutes, Clinics, and Hospitals. The Cancer Research Institutes is projected to witness significant market share during forecast period.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.73% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Immunotherapy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Immunotherapy Market, including Amgen Inc., AstraZeneca PLC, Avid Bioservices, Inc., Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GSK PLC, Janssen Global Services, LLC, Merck & Co., Inc., Novartis International AG, OSE Immunotherapeutics SA, and Pfizer, Inc..

The report provides insights on the following pointers:

Market Penetration: Provides comprehensive information on the market offered by the key players
Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

What is the market size and forecast of the Global Cancer Immunotherapy Market?
What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Immunotherapy Market during the forecast period?
Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Immunotherapy Market?
What is the competitive strategic window for opportunities in the Global Cancer Immunotherapy Market?
What are the technology trends and regulatory frameworks in the Global Cancer Immunotherapy Market?
What is the market share of the leading vendors in the Global Cancer Immunotherapy Market?
What modes and strategic moves are considered suitable for entering the Global Cancer Immunotherapy Market?

Frequently Asked Questions about the Global Cancer Immunotherapy Market

What is the estimated value of the Global Cancer Immunotherapy Market?

The Global Cancer Immunotherapy Market was estimated to be valued at $69.63 Billion in 2022.

What is the growth rate of the Global Cancer Immunotherapy Market?

The growth rate of the Global Cancer Immunotherapy Market is 5.5%, with an estimated value of $107.11 Billion by 2030.

What is the forecasted size of the Global Cancer Immunotherapy Market?

The Global Cancer Immunotherapy Market is estimated to be worth $107.11 Billion by 2030.

Who are the key companies in the Global Cancer Immunotherapy Market?

Key companies in the Global Cancer Immunotherapy Market include Amgen Inc., AstraZeneca PLC, Avid Bioservices, Inc., Bayer AG, Bristol, Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, ELI Lilly and Company, F. Hoffmann and La Roche Ltd.

Report Attribute	Details
No. of Pages	233
Published	May 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 69.63 Billion
Forecasted Market Value ( USD ) by 2030	$ 107.11 Billion
Compound Annual Growth Rate	5.5%
Regions Covered	Global
No. of Companies Mentioned	15

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cancer Immunotherapy Market, by Product, 2022 vs 2030
4.3. Cancer Immunotherapy Market, by Function, 2022 vs 2030
4.4. Cancer Immunotherapy Market, by End-User, 2022 vs 2030
4.5. Cancer Immunotherapy Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer patients worldwide
5.1.1.2. Increasing adoption of advanced cancer therapeutics
5.1.1.3. Surging investments in research and development activities of cancer treatment
5.1.2. Restraints
5.1.2.1. Capital intensive treatment and procedures
5.1.3. Opportunities
5.1.3.1. Extensive development of bioinformatics tools in drug development process
5.1.3.2. Growing number of clinical trials for cancer immunotherapy
5.1.4. Challenges
5.1.4.1. Complications in cancer limiting the immune response
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Cancer Immunotherapy Market, by Product

6.1. Introduction
6.2. Cell Therapies
6.2.1. Chimeric Antigen Receptor T Cell Therapy
6.2.2. Dendritic Cells
6.3. Checkpoint Inhibitors
6.3.1. Cytotoxic T-Lymphocyte-Associated Protein-4
6.3.2. Programmed Death 1 & Programmed Death Ligand 1
6.4. Immunomodulators
6.4.1. Granulocyte-Macrophage Colony-Stimulating Factor
6.4.2. Interferons
6.4.3. Interleukins
6.4.4. Oncolytic Virus
6.5. Monoclonal Antibodies
6.5.1. Bispecific Monoclonal Antibodies
6.5.2. Conjugated Monoclonal Antibodies
6.5.3. Naked Monoclonal Antibodies
6.6. Vaccines
6.6.1. Prophylactic Vaccines
6.6.2. Therapeutic Vaccines

7. Cancer Immunotherapy Market, by Function

7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Head & Neck Cancer
7.5. Lung Cancer
7.6. Melanoma
7.7. Multiple Myeloma
7.8. Prostate Cancer

8. Cancer Immunotherapy Market, by End-User

8.1. Introduction
8.2. Cancer Research Institutes
8.3. Clinics
8.4. Hospitals

9. Americas Cancer Immunotherapy Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cancer Immunotherapy Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario

13. Company Usability Profiles

13.1. Amgen Inc.
13.2. AstraZeneca PLC
13.3. Avid Bioservices, Inc.
13.4. Bayer AG
13.5. Bristol-Myers Squibb
13.6. C.H. Boehringer Sohn AG & Ko. KG
13.7. ELI Lilly and Company
13.8. F. Hoffmann-La Roche Ltd
13.9. Gilead Sciences, Inc.
13.10. GSK PLC
13.11. Janssen Global Services, LLC
13.12. Merck & Co., Inc.
13.13. Novartis International AG
13.14. OSE Immunotherapeutics SA
13.15. Pfizer, Inc.

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. CANCER IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. CANCER IMMUNOTHERAPY MARKET SIZE, 2022 VS 2030
FIGURE 3. CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 4. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 5. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)
FIGURE 6. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 7. CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 8. CANCER IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 9. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 10. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 11. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 14. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 16. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 17. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 4. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 5. CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 6. CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2030 (USD BILLION)
TABLE 7. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD BILLION)
TABLE 8. CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD BILLION)
TABLE 9. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 10. CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD BILLION)
TABLE 11. CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY REGION, 2018-2030 (USD BILLION)
TABLE 12. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2030 (USD BILLION)
TABLE 13. CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 14. CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD BILLION)
TABLE 15. CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD BILLION)
TABLE 16. CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD BILLION)
TABLE 17. CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD BILLION)
TABLE 18. CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2018-2030 (USD BILLION)
TABLE 19. CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 20. CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD BILLION)
TABLE 21. CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD BILLION)
TABLE 22. CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD BILLION)
TABLE 23. CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD BILLION)
TABLE 24. CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 25. CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD BILLION)
TABLE 26. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD BILLION)
TABLE 27. CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD BILLION)
TABLE 28. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 29. CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 30. CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 31. CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 32. CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 33. CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD BILLION)
TABLE 34. CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD BILLION)
TABLE 35. CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD BILLION)
TABLE 36. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 37. CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD BILLION)
TABLE 38. CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD BILLION)
TABLE 39. CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD BILLION)
TABLE 40. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 41. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 42. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 43. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 44. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 45. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 46. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 47. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 48. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 49. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 50. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 51. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 52. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 53. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 54. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 55. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 56. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 57. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 58. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 59. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 60. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 61. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 62. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 63. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 64. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 65. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 66. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 67. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 68. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 69. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 70. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 71. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 72. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 73. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 74. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 75. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 76. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 77. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 78. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 79. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 80. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 81. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
TABLE 82. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 83. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 84. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 85. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 86. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 87. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 88. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 89. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 90. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 91. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 92. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 93. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 94. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 95. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 96. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 97. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 98. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 99. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 100. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 101. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 102. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 103. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 104. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 105. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 106. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 107. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 108. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 109. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 110. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 111. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 112. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 113. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 114. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 115. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 116. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 117. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 118. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 119. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 120. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 121. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 122. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 123. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 124. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 125. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 126. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 127. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 128. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 129. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 130. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 131. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 132. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 133. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 134. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 135. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 136. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 137. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 138. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 139. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 140. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 141. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 142. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 143. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 144. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 145. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 146. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 147. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 148. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 149. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 150. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 151. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 152. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 153. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 154. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 155. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 156. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 157. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 158. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 159. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 160. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 161. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 162. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 163. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 164. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 165. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 166. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 167. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 168. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 169. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 170. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 171. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 172. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 173. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 174. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 175. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 176. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 177. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 178. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 179. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 180. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 181. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 182. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 183. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 184. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 185. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 186. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 187. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 188. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 189. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 190. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 191. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 192. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 193. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 194. VIETNAM CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 204. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 205. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 206. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 207. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 208. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 209. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 210. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 211. DENMARK CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 212. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 213. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 214. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 215. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 216. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 217. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 218. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 219. EGYPT CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 220. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 221. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 222. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 223. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 224. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 225. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 226. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 227. FINLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 228. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 229. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 230. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 231. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 232. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 233. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 234. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 235. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 236. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 237. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 238. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 239. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 240. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 241. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 242. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 243. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 244. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 245. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 246. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 247. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 248. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 249. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 250. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 251. ISRAEL CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 252. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 253. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 254. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 255. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 256. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 257. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 258. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 259. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 260. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 261. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 262. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 263. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 264. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 265. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 266. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 267. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 268. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 269. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 270. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 271. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 272. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 273. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 274. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 275. NIGERIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 276. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 277. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 278. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 279. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 280. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 281. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 282. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 283. NORWAY CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 284. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 285. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 286. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 287. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 288. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 289. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 290. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 291. POLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 292. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 293. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 294. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 295. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 296. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 297. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 298. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 299. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 300. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 301. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 302. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 303. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 304. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 305. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 306. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 307. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 308. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 309. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 310. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 311. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 312. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 313. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 314. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 315. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 316. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 317. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 318. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 319. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 320. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 321. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 322. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 323. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 324. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 325. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 326. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 327. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 328. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 329. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 330. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 331. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 332. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 333. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 334. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD BILLION)
TABLE 335. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD BILLION)
TABLE 336. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 337. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 338. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2030 (USD BILLION)
TABLE 339. SWEDEN CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD BILLION)
TABLE 340. SWITZERLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 341. SWITZERLAND CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2030 (USD BILLION)
TABLE 342. SWITZERLAND CANCER IMMUNO